To Top

Privacy Statement

This privacy policy sets out how CTFarmtoFood.org uses and protects any information that you give CTFarmtoFood.org when you use this website.
CTFarmtoFood.org is committed to ensuring that your privacy is protected. Should we ask you to provide certain information by which you can be identified when using this website, then you can be assured that it will only be used in accordance with this privacy statement.
CTFarmtoFood.org may change this policy from time to time by updating this page. You should check this page from time to time to ensure that you are happy with any changes. This policy is effective from May 9, 2013.

What we collect
We may collect the following information:

Name, contact information including email address
Messages that you provide for feedback and information for your legislators
IP address to prevent SPAM and ensure quality of messages coming into our site

What we do with the information we gather
We require this information to understand your needs and provide you with a better service, and in particular for the following reasons:

Internal record keeping.
Send information to legislators.
We may periodically send emails news and updates, you may unsubscribe at anytime.
From time to time, we may also use your information to contact you for market research purposes. We may contact you by email, phone, fax or mail.
We may use the information to customize the website according to your interests.
We will never sell your information.

Security
We are committed to ensuring that your information is secure.

BARDA, Department of Defense, and SAb Biotherapeutics to Partner to Develop a Novel COVID-19 Therapeutic

April 6, 2020 by admin

Published by Medical Counter Measures

A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership between BARDA, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND), and SAb Biotherapeutics, Inc. (SAb), of Sioux Falls, South Dakota.

Using an interagency agreement with JPEO’s Medical CBRN Defense Consortium, BARDA transferred approximately $7.2 million in funding to (JPEO – CBRND) to support SAb to complete manufacturing and preclinical studies, with an option to conduct a Phase 1 clinical trial.

Read the full press release here.

Agri-Pulse: Can cows be used to fight coronavirus?

March 30, 2020 by admin

Bovine plasma donors genetically engineered to produce human antibodies are in the front lines of the struggle against coronavirus.

SAB Biotherapeutics, a Sioux Falls, S.D., biotechnology company that has been successfully testing use of antibodies from cows to fight diseases such as another coronavirus, Middle East respiratory syndrome, now is engaged in developing a treatment for COVID-19, the disease caused by the novel coronavirus.

Read the full article here.

Times Argus: High-tech chestnuts: US to consider genetically altered tree

November 7, 2019 by admin

SYRACUSE, N.Y. (AP) — Chestnuts harvested from high branches on a chilly fall morning look typical: they’re marble sized, russet colored and nestled in prickly burs. But many are like no other nuts in nature.

In a feat of genetic engineering, about half the chestnuts collected at this college experiment station feature a gene that provides resistance to blight that virtually wiped out the American chestnut tree generations ago.

Read more here.